ERBB2 and non-small cell lung carcinoma: This is in contrast with trastuzumab emtansine, which demonstrated limited efficacy in HER2-overexpressed NSCLC; DCR were only 7% and 30% in IHC 2+ and 3+ cohorts, respectively [7, 44].